Eicosanol

Synopsis

Eicosanol (1-Eicosanol / Arachidyl Alcohol): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Synonyms

Eicosanol—formally designated 1-eicosanol or icosan-1-ol by IUPAC nomenclature—is a long-chain primary fatty alcohol belonging to the class of saturated aliphatic alcohols. It is also widely known as eicosyl alcohol, and its systematic IUPAC name is 1-icosanol. In the cosmetics and industrial chemistry literature the compound is most commonly encountered under the name arachidyl alcohol (also rendered as arachidic alcohol, arachinyl alcohol, arachic alcohol, or arachyl alcohol), a designation that reflects its close relationship to arachidic acid (eicosanoic acid), a C20 saturated fatty acid found in peanut (Arachis) oil. It is a straight-chain fatty alcohol with 20 carbon atoms, typically obtained via the hydrogenation of arachidic acid or arachidonic acid, both of which are present in peanut oil; its name derives from the Latin name of the peanut plant (arachis). Additional synonyms recorded in chemical databases include n-eicosanol, eicosanol-(1), pri-n-eicosyl alcohol, alcohol C20, and icosyl alcohol. Its CAS Registry Number is 629-96-9; its EINECS number is 211-119-4.

Chemical Structure and Physical Properties

1-Eicosanol is a long-chain fatty alcohol with the molecular formula C₂₀H₄₂O. It is a white, waxy solid with a molecular weight of 298.55 g/mol and a melting point of 63–65 °C. Its molecular weight is recorded as 298.52 g/mol in some references, consistent with the formula C₂₀H₄₁OH. The compound belongs to the class of fatty alcohols, which are defined by a terminal hydroxyl group on a long unbranched alkyl chain. Per ChEBI, it is described as a fatty alcohol consisting of a hydroxy function at C-1 of an unbranched saturated chain of 20 carbon atoms. 1-Eicosanol is insoluble in water but soluble in organic solvents such as ethanol and ether, which is typical for long-chain alcohols. The polymorphism of 1-eicosanol has been studied by X-ray powder diffraction, differential scanning calorimetry (DSC), Raman scattering, and IR spectroscopy.

Natural Sources

1-Eicosanol is broadly distributed in the natural world, present in plant waxes, insect waxes, seeds, and microbial metabolites. It is a naturally occurring component of various plant waxes and has been isolated from several sources, including beeswax and carnauba wax. It is a long-chain fatty alcohol and volatile organic compound that can be isolated from the leaves of Leea indica and produced by Bacillus velezensis ZJ1. It has also been identified as a natural product isolated from Hypericum carinatum. According to research on H. carinatum, five known compounds were characterized from this species, including 1-eicosanol alongside sitosterol, stigmasterol, and campesterol.

As a member of the policosanol family of long-chain aliphatic alcohols, eicosanol is found in many of the same sources as better-known higher fatty alcohols such as octacosanol and triacontanol. Policosanol was originally derived from sugar cane, but the constituent chemicals can also be isolated from beeswax, cereal grains, grasses, leaves, fruits, nuts, and seeds of many foods. Various fatty alcohols are found in beeswax, insect wax, and in the waxy film that plants have over their leaves and fruits. Additionally, known botanical sources identified in chemical literature include Linum usitatissimum (flax) and Piper methysticum (kava).

Within policosanol mixtures, eicosanol (C20) is a recognized minor-to-moderate constituent. Policosanol isolated from sugar cane wax consists of different components such as octacosanol (66%), hexacosanol (7%), triacontanol (12%), and eicosanol, tetracosanol, nonacosanol, dotriacontanol, tetratriacontanol, and heptacosanol (collectively about 15%). By contrast, the composition profile can differ markedly by source: in policosanol extracted from wheat germ, the aliphatic alcohol fractions ranged from C18 to C32, with eicosanol (C20-OH) accounting for over 50% of the total aliphatic alcohol content—the single most abundant component at approximately 54.96%. In beeswax-derived policosanol, eicosanol is present at 0.5–7% alongside docosanol, tetracosanol, hexacosanol, octacosanol, triacontanol, dotriacontanol, and tetratriacontanol.

Common Forms and Preparations

Commercially, 1-eicosanol is available as a white waxy powder or solid. In research and industrial contexts it is used at purities typically ranging from 85% to 99% (with grades marketed at ≥90%, 96%, and 98% GC purity). It has applications in various industries, including cosmetics, where it serves as an emollient and thickening agent, as well as in the production of surfactants and lubricants. As arachidyl alcohol, it functions as an emollient and thickener and is often incorporated into cosmetics to prevent moisture loss and improve skin smoothness.

In the dietary supplement context, eicosanol is not commonly marketed as a standalone ingredient. Instead, it is encountered as a constituent fraction within policosanol supplements, which are standardized mixtures of long-chain aliphatic alcohols. Policosanol has been widely used in the fields of dietary food supplements, food additives, cosmetics, pharmaceuticals, and animal feed additives. Extraction from natural wax sources is performed primarily via saponification. Policosanol is mainly fabricated from sugar cane by hydrolytic cleavage of the wax and subsequent purification; currently, policosanol is mostly fabricated via saponification. A nanoemulsion formulation approach has been investigated to improve the poor oral bioavailability of these waxy alcohols. Despite the wide array of reported biological activities of policosanol, its bioavailability was reported to be between 5% and 12%, with absorption after oral administration falling within that range.

2. Traditional and Historical Use

Insect Wax Traditions (China and East Asia)

The richest historical tradition involving the wax matrices in which eicosanol and related fatty alcohols naturally occur is found in East Asian insect-wax practices. The Chinese white wax scale (Ericerus pela) is a famous insect species because of its role in economic production in China, and these insects have been bred there for over one thousand years. Insect wax has been used in printing, candle production, and traditional medicine for a long time. It has also been used as a cosmetic material, insulative coating, and fruit preservative. While historical references do not single out eicosanol by name—the compound would not have been chemically identified in these eras—the policosanol-containing wax matrix in which eicosanol is present formed the material basis for these traditional applications.

Botanical Wax Uses and Traditional Dietary Exposure

Carnauba wax (from the Brazilian palm Copernicia prunifera) and beeswax, both containing 1-eicosanol, have histories of use as food coatings, medicine-delivery vehicles, and preservatives across South American, African, and European folk traditions. Although historical documentation of specific therapeutic use of isolated eicosanol does not exist in the peer-reviewed record—eicosanol is a trace component within complex wax matrices—the broader class of long-chain fatty alcohols from plant waxes appears throughout the ethnobotanical literature of sugar cane cultivation regions. Policosanol gained popularity as a natural alternative to statins, especially in Cuba, where it was originally developed and extensively studied. It was initially isolated from sugar cane wax by Cuban researchers and developed by Cuban Dalmer laboratories. The Cuban research program, which began in the 1990s, drew on the traditional practice of consuming whole, unrefined cane sugar and cane extracts in the Caribbean, where such preparations deliver small but consistent amounts of long-chain fatty alcohols including eicosanol.

Flax and Kava Contexts

Chemical databases record Linum usitatissimum (flax) and Piper methysticum (kava) as botanical sources from which 1-eicosanol has been identified. Flax has been cultivated and consumed for millennia in the Near East, Central Asia, and Europe, where its seed oil and fiber have served nutritional and textile purposes. Kava has been used ceremonially and medicinally in Pacific Island cultures for centuries as a beverage prepared from the roots of Piper methysticum. In neither case was eicosanol specifically recognized or isolated as an active component in historical practice; its presence is a phytochemical finding from modern analytical chemistry.

3. Key Constituents, Chemical Class, and Mechanisms of Action

Chemical Classification

Eicosanol belongs to the family of long-chain primary aliphatic alcohols, also termed fatty alcohols or, in the context of mixtures, policosanols. Policosanol is the term for a mixture of very long-chain aliphatic alcohols (24–34 carbon length) that are naturally found in a variety of plant germs, plant and insect waxes, seeds, leaves, and grasses. Eicosanol, at 20 carbons, sits at the lower end of this spectrum but is structurally homologous to the better-studied octacosanol (C28) and triacontanol (C30). Recent interest in insect wax has increased in the pharmaceutical field because of its policosanol moieties, a family of high-molecular-weight and saturated aliphatic primary alcohols (C20–C36).

Antioxidant Properties

1-Eicosanol is a naturally occurring compound with antioxidant effect extracted from Hypericum carinatum. However, the evidence for significant radical-scavenging activity within the policosanol class as a whole is not unambiguous. A study specifically examining policosanol fractions found that policosanol had no apparent anti-LDL oxidation activity when 1-tetracosanol, 1-hexacosanol, and 1-octacosanol were incubated in human LDL; policosanol also possessed no scavenging activity on the free radical 2,2-diphenyl-1-picrylhydrazyl. These data provided evidence that the cholesterol-lowering activity of policosanol is partially mediated by its inhibition on the absorption of bile acids, but disproved the claim that policosanol is an antioxidant. The antioxidant attribution specifically to 1-eicosanol from H. carinatum is based on in-vitro studies at the laboratory chemical level rather than human clinical data.

Antifungal Properties

1-Eicosanol inhibits mycelial growth of Alternaria solani and Botrytis cinerea. The bacterium Bacillus velezensis ZJ1, isolated from the stem of Buddleja lindleyana, produces volatile organic compounds (VOCs) that exhibit significant antifungal activity against Alternaria solani and Botrytis cinerea. These organisms cause tomato early blight and gray mold, respectively. Eicosanol has been identified among the VOCs produced by this endophytic bacterium and is associated with antifungal biocontrol potential. This activity remains at the experimental/agronomic research level and has not been evaluated in human or mammalian systems.

Antimicrobial Activity (In Vitro)

1-Eicosanol shows minimum inhibitory activity against both Staphylococcus aureus and Propionibacterium acnes, with MIC values greater than 800.0 µg/mL, indicating weak inhibitory effects against these bacteria. This suggests that, at least against common skin pathogens tested in vitro, eicosanol is not a potent antimicrobial agent in isolation.

Cholesterol-Related Mechanisms (as Part of the Policosanol Class)

As a constituent of policosanol mixtures, eicosanol shares the mechanistic context of the broader policosanol research literature, though the bulk of mechanistic work focuses on octacosanol (C28) and triacontanol (C30). It is not clear whether policosanol inhibits 3-hydroxyl-3-methylglutaryl CoA (HMG-CoA) reductase or increases receptor-mediated uptake of LDL cholesterol by the liver in a way that improves LDL metabolism. Animal studies suggest an additional pathway: cholesterol-lowering activity of policosanol is partially mediated by inhibition of the absorption of bile acids. Besides improving serum lipid profile, policosanol modifies several other cardiovascular disease risk factors by reducing LDL oxidation, platelet aggregation, and endothelial cell damage.

Policosanol (PCS) is a mixture of long-chain linear aliphatic alcohols that are present in beeswax, potatoes, rice bran, and in sugar cane; the mechanism behind PCS-induced cholesterol-lowering has not yet been fully elucidated.

Antiplatelet Effects (as Part of the Policosanol Class)

Policosanol has significant antiplatelet effects in both humans and animal models. In a double-blind randomized human study, study subjects were randomized to receive, under double-blind conditions, placebo or policosanol (20 or 40 mg/day) for 30 days once a day, with blood sampling performed at baseline and after 30 days; platelet aggregation was induced with three aggregating agents: arachidonic acid, collagen, and low doses of ADP. Policosanol (20 and 40 mg/day) moderately yet significantly reduced platelet aggregation, but no differences were observed in the effects produced by either dose. The specific contribution of eicosanol to antiplatelet effects within such mixtures has not been isolated in human studies.

Kinase Substrate Activity

1-Eicosanol demonstrates substrate activity at 6xHis-tagged Streptococcus mutans UdpK expressed in Escherichia coli BL-21(DE3); bioactivity assessed by measuring ADP levels in the presence of ATP/NADH using a PK/LDH coupled assay revealed an activity rate of 1.3 µmol/mg/min. This is a biochemical finding from in vitro research with unclear physiological significance for human health.

4. Scientific Evidence by Area of Use

4a. Lipid/Cholesterol Modulation

Important framing note: The clinical evidence for lipid effects relates almost entirely to policosanol mixtures (in which eicosanol is a minor-to-moderate fraction), not to isolated 1-eicosanol. Studies conducted on policosanol cannot be interpreted as evidence for eicosanol in isolation.

Policosanol was developed in Cuba, and the majority of the research—over 60 clinical trials—was carried out there. These Cuban researchers suggested that policosanol performs equal to or better than standard pharmaceuticals used to treat abnormalities of cholesterol metabolism such as lovastatin and probucol. Policosanols are known to have a number of beneficial effects on blood lipid health, including lowering blood cholesterol levels, reducing low-density lipoproteins (LDL), increasing high-density lipoproteins (HDL), and reducing blood triglycerides.

However, independent replication has been problematic. Recent studies produced contraindicating results compared with the Cuban research. Policosanol may modestly modulate lipid profiles and blood pressure, but effects are inconsistent across studies. A key source of discrepancy is the variation in policosanol composition by botanical source: the composition of rice wax is different from sugar cane wax, most notably due to a lower concentration of octacosanol and a higher concentration of triacontanol. Direct comparisons of the two bodies of findings have been limited by differences in regional dietary patterns and by the unknown variability of the composition of the policosanol products that were tested.

In the animal model literature, hamsters given 0.38–1.5 g/kg diet had serum total cholesterol lowered by 15–25% and had high-density lipoprotein cholesterol elevated by 7–16.8%; policosanol also increased the excretion of acidic sterols by 25–73%.

Evidence strength: Preliminary-to-mixed for the policosanol mixture class; not established for isolated eicosanol.

4b. Antifungal and Antimicrobial Effects

1-Eicosanol inhibits mycelial growth of Alternaria solani and Botrytis cinerea and is applicable to research related to tomato early blight and tomato gray mold. These findings derive from microbiology and plant pathology research on volatile compounds produced by endophytic bacteria. The volatile organic compounds (VOCs) from Bacillus velezensis ZJ1 exhibited significant antifungal activity against Alternaria solani and Botrytis cinerea, identified via gas chromatography–mass spectrometry of solid-phase microextraction samples.

Against human skin pathogens in vitro, the evidence indicates weak activity: 1-eicosanol shows minimum inhibitory activity against both Staphylococcus aureus and Propionibacterium acnes, with MIC values greater than 800.0 µg/mL, indicating weak inhibitory effects.

Evidence strength: In vitro and agronomic/microbiological only. No human clinical trials of eicosanol as an antimicrobial or antifungal agent have been reported.

4c. Antioxidant Effects

The antioxidant attribution to 1-eicosanol originates primarily from its isolation from Hypericum carinatum. 1-Eicosanol is a natural product with antioxidant activity isolated from Hypericum carinatum. In the phytochemical study that identified it, the compound was isolated alongside benzophenones and phloroglucinol derivatives; however, antioxidant activity in that paper was attributed primarily to the benzophenone cariphenone A, which showed inhibition of chemiluminescence similar to quercetin, whereas the role of the eicosanol itself is not separately characterized. Compounds including the benzophenones were evaluated for their total antioxidant capacity through a total radical-trapping parameter assay; only cariphenone A showed moderate antioxidant activity.

In the broader policosanol literature, one hamster study specifically concluded that policosanol had no apparent anti-LDL oxidation activity when major constituent alcohols (tetracosanol, hexacosanol, octacosanol) were incubated in human LDL, and also possessed no scavenging activity on the free radical DPPH.

Evidence strength: Very preliminary; largely in vitro or incidental to phytochemical isolation studies. No human clinical trials.

4d. Cardiovascular and Platelet Effects

Policosanol mixtures—of which eicosanol is a constituent—have been extensively evaluated in Cuban clinical trials for cardiovascular benefits. Previous studies indicated that policosanol has a wide variety of biological functions including lipid-lowering effects and prevention of type II hypercholesterolemia, type II diabetes, and oxidative stress. Among specific cardiovascular actions, platelet aggregation inhibition is the most consistently demonstrated pharmacodynamic effect of policosanol mixtures in human studies.

A double-blind randomized study enrolled both healthy volunteers and type II hypercholesterolaemic patients to receive placebo or policosanol at 20 or 40 mg/day for 30 days. The antiplatelet effects induced by 40 mg/day policosanol administered for 30 days were similar to the effects induced by 20 mg/day policosanol; thus, no enhancement of the response was achieved with the higher dose. Several clinical studies have shown that policosanol decreased arterial pressure compared with placebo.

Evidence strength: Moderate (for policosanol mixtures, particularly Cuban-derived sugar-cane policosanol); weak-to-none for isolated eicosanol. Independent non-Cuban trials have not consistently replicated lipid-lowering effects.

4e. Neuroprotective and Fatigue-Related Effects

Policosanol may have a neuroprotective effect through its antioxidant activity, but clinical evidence is lacking. Previous studies focus on policosanol alleviating fatigue, but the signal pathways and target genes regulated by policosanol are poorly understood. These claims refer to the policosanol class as a whole; no clinical studies isolate eicosanol's contribution to these effects.

Evidence strength: Preliminary; animal and in vitro only for the policosanol class. No human clinical trials specifically addressing eicosanol's neuroprotective or anti-fatigue properties.

4f. Anti-Arthritic and Anti-Inflammatory Effects

A PMC-published study examined the anti-arthritic activity of milk thistle (Silybum marianum) oil, in which 1-eicosanol was employed as an analytical standard for the policosanol fraction. The maximum inhibition of bovine serum protein denaturation (92.53%) and egg albumin denaturation (86.36%) were observed in immature seed oil compared to mature seed oil, with a high total policosanol content. A high correlation was found between total policosanol content, anti-arthritic activity, and antioxidant capacity of oil. However, this experiment was conducted in vitro and the anti-arthritic activity was attributed to the total policosanol fraction, not to eicosanol specifically.

Evidence strength: In vitro only; no human studies. Eicosanol's individual contribution within the mixture is not established.

4g. Colitis and Gut Inflammation

A publication suggests that octacosanol (C28), a major component of policosanol, can inhibit dextran sulfate sodium (DSS)-induced colitis in an animal model. Eicosanol has not been individually studied in this context; evidence for eicosanol per se is absent.

Evidence strength: Animal only, and attributed to a different congener (octacosanol), not eicosanol.

5. Body Systems and Health Areas Associated with Eicosanol

Cardiovascular system: As a constituent of policosanol mixtures, eicosanol is present in formulations studied for cholesterol modulation, LDL reduction, HDL elevation, platelet aggregation inhibition, and blood pressure effects. The mechanistic and clinical evidence is ascribed to the mixture and primarily to octacosanol and triacontanol as dominant components.
Skin and integumentary system: Eicosanol (as arachidyl alcohol) serves as an emollient and thickening agent in cosmetics, preventing moisture loss and improving skin smoothness. This is a well-established topical application.
Immune/Antifungal context: In laboratory research, eicosanol has demonstrated mycelial growth inhibition against plant fungal pathogens; its role in mammalian immune responses or human fungal infections has not been studied.
Nervous system: Fatigue-alleviating and neuroprotective properties are attributed to the policosanol class to which eicosanol belongs, but these claims derive from animal and mechanistic work with no human clinical confirmation for eicosanol specifically.
Digestive system: Bile acid excretion modulation has been proposed as a partial mechanism for the cholesterol-lowering effects of policosanol, and eicosanol is part of the mixture in which this has been studied. No human data isolate eicosanol's role.

6. Dosage Forms and Dosages Reported in the Literature

Because 1-eicosanol is not marketed as an isolated clinical agent, dosage information derives from policosanol mixture studies in which eicosanol is a fraction. The proportional dose of eicosanol within any policosanol preparation will depend on source and composition.

Policosanol is typically initiated at 5 mg/day and titrated up to 20 mg/day for hypercholesterolemia.
Adjunctive use of 40 mg/day for 30 days has been reported with antiplatelet regimens after percutaneous stent implantation.
A randomized double-blind study compared policosanol doses of 20 mg/day versus 40 mg/day administered once daily for 30 days in healthy volunteers and type II hypercholesterolaemic patients.
In a study that followed 27,879 participants for up to 4 years, only 0.31% reported adverse effects, primarily weight loss, increased urination, and insomnia.

No specific clinical dosing information exists for eicosanol used in isolation as a supplement. In analytical chemistry settings, 1-eicosanol is used as an internal standard in GC analysis of policosanol-containing preparations. An internal standard working solution has been prepared by accurately weighing 10 mg of 1-eicosanol (97%) dissolved in 100 mL of chloroform and then diluted to 10 µg/mL solution for quality-control purposes in tablet analysis.

7. Safety Considerations and Interactions

General Safety Profile of the Policosanol Class

Policosanol appears to be safe at the recommended dose, with only mild short-term side effects reported in trials. Policosanol is well-tolerated with an adverse event profile comparable to placebo, though long-term safety has not been established. Studies in rats and mice demonstrated no adverse effects on fertility, reproduction, teratogenesis, or development at doses equivalent to 1,500 times the normal human dose of 20 mg/day.

Antiplatelet and Anticoagulant Interactions

The most clinically significant safety consideration for policosanol—and by extension for preparations containing eicosanol—relates to platelet function. Because of its effects on platelet adhesiveness, policosanol can have additive effects with all anticoagulant and antiplatelet medications. Policosanol might slow blood clotting; taking policosanol along with medications that also slow clotting might increase the chances of bruising and bleeding. It is recommended to stop using policosanol at least 2 weeks before a scheduled surgery.

Specific anticoagulant interaction data: A study in 11 healthy men receiving warfarin 25 mg before and after treatment with policosanol 10 mg twice daily for 2 weeks found no effect of policosanol on the pharmacokinetics of (S)- or (R)-warfarin; policosanol also did not alter the response to warfarin on platelet aggregation. Despite this finding, caution in combination with warfarin is still noted in the literature given the pharmacodynamic antiplatelet activity. Experimental data indicate that potential drug–drug interactions between policosanol and drugs metabolized through the cytochrome P450 hepatic system are not expected, but pharmacodynamic interactions cannot be excluded.

Antihypertensive Drug Interactions

Several clinical studies have shown that policosanol decreased arterial pressure compared with placebo, and a pharmacological interaction with beta-blockers was experimentally proven; therefore, clinical drug–drug interactions between policosanol and beta-blockers can be expected. Animal studies suggest policosanol may increase the hypotensive effects of beta-blockers and nitroprusside. Taking policosanol along with medications used for lowering high blood pressure might cause blood pressure to go too low, as policosanol might decrease blood pressure in some people.

Use in Pregnancy and Breastfeeding

Information regarding safety and efficacy in pregnancy and lactation is lacking. No clinical data support the safety of eicosanol-containing policosanol preparations in pregnant or breastfeeding individuals.

Cosmetic Safety (Topical)

Arachidyl alcohol (icosan-1-ol) is a waxy substance used as an emollient in cosmetics. Its use in topical cosmetic preparations is longstanding and considered safe at concentrations used in these products, consistent with its classification as a fatty alcohol and its non-reactive, waxy character. The compound is insoluble in water and has no documented sensitization concerns in the peer-reviewed literature at concentrations used in cosmetics.

Bioavailability Limitation

These fatty alcohols are poorly soluble in lipid carriers and completely insoluble in aqueous carriers, which greatly reduces their availability in the digestive tract. This is relevant to both efficacy and toxicity assessment: poor bioavailability means that systemic exposure from oral administration is substantially lower than the administered dose, which may contribute to the favorable safety profile but also to the inconsistent clinical efficacy data.

8. Regulatory and Analytical Context

1-Eicosanol is not listed as an approved drug in any major jurisdiction. As a constituent of policosanol-containing dietary supplements, it falls under the general regulatory frameworks for botanical dietary supplements (e.g., DSHEA in the United States). Policosanol has been widely used in the fields of dietary food supplements, food additives, cosmetics, pharmaceuticals, and animal feed additives. In analytical chemistry, 1-eicosanol plays an important role as a reference standard: 1-eicosanol has been used in gradient HPLC–charged aerosol detection methods for the detection of different lipids, and as an internal standard during determination of policosanol's high-molecular-weight alcohols in fish oil by GC.

Efficacy may depend on formulation; policosanol is well-tolerated with an adverse event profile comparable to placebo. The overall body of clinical evidence for the policosanol mixture class is characterized by a significant divide between the early Cuban research reporting substantial lipid-lowering effects and later independent trials—conducted outside Cuba and using policosanol from different botanical sources—which have not consistently replicated those findings. The function investigations of higher aliphatic alcohols (policosanol) are still in their infancy.